Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancer-Reference-Cited by-同舟云学术

Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancer

Author:

Wang Nan¹,Zhao Qilin²,Huang Yutang¹,Wen Chunjie¹,Li Yaji¹,Bao Meihua³⁴,Wu Lanxiang¹⁵^ORCID

Affiliation:

1. Institute of Life Sciences, Chongqing Medical University, Chongqing, China

2. Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

3. Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, 410219, China

4. Academician Workstation, Changsha Medical University, Changsha, 410219, China

5. Molecular Medicine Diagnostic and Testing Center, Chongqing Medical University, Chongqing, China

Abstract

Lnc-TMEM132D-AS1 induces acquired resistance to osimertinib in NSCLC by the miR-766-5p/ENTPD1 axis.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Chongqing

Chongqing Medical University

Science and Technology Planning Project of Yuzhong District of Chongqing City

Chongqing Municipal Education Commission Foundation

Publisher

Royal Society of Chemistry (RSC)

Subject

Genetics,Molecular Biology,Biochemistry

Link

Reference45 articles.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献